Bath Savings Trust Co Acquires New Shares in Cencora, Inc. (NYSE:COR)

Bath Savings Trust Co bought a new position in Cencora, Inc. (NYSE:COR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 859 shares of the company's stock, valued at approximately $239,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COR. Perigon Wealth Management LLC increased its stake in shares of Cencora by 15.5% during the 4th quarter. Perigon Wealth Management LLC now owns 2,427 shares of the company's stock valued at $585,000 after acquiring an additional 325 shares during the last quarter. Asset Dedication LLC increased its position in Cencora by 682.2% during the fourth quarter. Asset Dedication LLC now owns 352 shares of the company's stock worth $79,000 after purchasing an additional 307 shares during the last quarter. Foster & Motley Inc. raised its stake in Cencora by 4.1% during the fourth quarter. Foster & Motley Inc. now owns 7,907 shares of the company's stock worth $1,777,000 after purchasing an additional 314 shares during the period. Busey Bank boosted its holdings in shares of Cencora by 9.2% in the 4th quarter. Busey Bank now owns 4,699 shares of the company's stock valued at $1,056,000 after purchasing an additional 395 shares during the last quarter. Finally, Mediolanum International Funds Ltd grew its stake in shares of Cencora by 16.7% during the 4th quarter. Mediolanum International Funds Ltd now owns 79,766 shares of the company's stock valued at $17,880,000 after buying an additional 11,426 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 0.0%

Shares of Cencora stock traded up $0.09 on Wednesday, hitting $291.64. 275,843 shares of the company's stock traded hands, compared to its average volume of 1,528,705. Cencora, Inc. has a 52-week low of $218.65 and a 52-week high of $309.35. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market cap of $56.53 billion, a P/E ratio of 41.49, a PEG ratio of 1.31 and a beta of 0.60. The firm's 50-day moving average is $285.59 and its 200 day moving average is $259.30.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.80 EPS. Equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,253 shares of company stock valued at $11,102,417 over the last three months. 10.80% of the stock is owned by insiders.

Analyst Ratings Changes

COR has been the topic of several research reports. UBS Group increased their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $274.00 to $337.00 in a report on Tuesday. Morgan Stanley set a $288.00 price objective on Cencora in a research note on Tuesday, April 15th. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.